Mind Medicine Analyst Ratings
Mind Medicine Analyst Ratings
Baird Starts Mind Medicine (MindMed) With Outperform Rating, $27 Price Target
Mind Medicine (MindMed) Inc.: Baird starts insurance with a rating that outperforms the market; target price is $27
Mind Medicine Analyst Ratings
HC Wainwright & Co. : The Mind Medicine (MNMD.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $35.00.
Mind Medicine Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $35 Price Target
Oppenheimer Reiterates Outperform on Mind Medicine, Lowers Price Target to $20
HC Wainwright & Co. : Maintaining the Mind Medicine (MNMD.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $75.00 to $35.00.
Mind Medicine Analyst Ratings
HC Wainwright & Co. Maintains Buy on Mind Medicine, Lowers Price Target to $35
Mind Medicine (MNMD.US) was first covered by Leerink Partners, which gave it an superior market rating, with a target price of $20.00.
Leerink Partners Initiates Coverage On Mind Medicine With Outperform Rating, Announces Price Target of $20
Mind Medicine Analyst Ratings
Mind Medicine Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $75 Price Target
Mind Medicine Analyst Ratings
Mind Medicine Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $75 Price Target